Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KJ015 Injection (Subcutaneous Injection) in Patients With HER2-Expressing Solid Tumors

NCT07036185 is registered in ClinicalTrials.gov with Shanghai Bao Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07036185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07036185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KJ015 Injection (Subcutaneous Injection) in Patients With HER2-Expressing Solid Tumors
Lead sponsor
Shanghai Bao Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 24, 2025
Completion date
April 30, 2027
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, breast cancer, colorectal cancer, gastric/gastroesophageal junction cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (nsclc)